Learn more →
Back to Expert Scholars
Cell Therapy / 细胞治疗Multiple Myeloma

Sham Mailankody

沙姆·马伦科迪

MBBS

🏢Memorial Sloan Kettering Cancer Center(纪念斯隆凯特琳癌症中心)🌐USA

Attending Physician, Myeloma Service & Associate Member骨髓瘤科主治医师暨副研究员

42
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Sham Mailankody is a leading MSK investigator in BCMA-targeted therapies for myeloma. He was a key clinical trialist for idecabtagene vicleucel (bb2121), the first approved BCMA CAR-T therapy, and continues to advance next-generation immunotherapy approaches.

Share:

🧪Research Fields 研究领域

Multiple Myeloma多发性骨髓瘤
BCMA-Targeted TherapyBCMA靶向治疗
Idecabtagene Vicleucel艾地苯醌维塞尤赛
CAR-T Clinical TrialsCAR-T临床试验

🎓Key Contributions 主要贡献

Idecabtagene Vicleucel (ide-cel) Development

Served as principal investigator at MSK for the KarMMa trial leading to FDA approval of ide-cel, the first BCMA-directed CAR-T cell therapy in relapsed/refractory myeloma in 2021.

BCMA-Targeted Therapy Landscape

Contributed clinical trial and translational research defining optimal sequencing of BCMA antibody-drug conjugates, bispecifics, and CAR-T therapies to maximize patient outcomes and manage resistance.

Real-World CAR-T Outcomes

Led MSK analyses characterizing real-world safety and efficacy of commercial BCMA CAR-T therapies, identifying predictors of response and toxicity to guide patient selection in clinical practice.

Representative Works 代表性著作

[1]

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma (KarMMa)

New England Journal of Medicine (2021)

Pivotal phase II trial demonstrating 73% ORR with ide-cel, establishing BCMA CAR-T as a treatment option in late-line myeloma.

[2]

BCMA-Targeted Therapies in Multiple Myeloma: A Review

Clinical Cancer Research (2022)

Comprehensive review comparing antibody-drug conjugates, bispecifics, and CAR-T approaches targeting BCMA in myeloma.

[3]

Real-World Outcomes with Commercial Ide-cel in Multiple Myeloma

Blood (2024)

Multi-center real-world analysis of ide-cel outcomes outside clinical trial settings, identifying prognostic factors.

🏆Awards & Recognition 奖项与荣誉

🏆American Society of Clinical Oncology (ASCO) Young Investigator Award
🏆MSK Investigator of the Year – Hematologic Oncology
🏆International Myeloma Society Young Investigator Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 沙姆·马伦科迪 的研究动态

Follow Sham Mailankody's research updates

留下邮箱,当我们发布与 Sham Mailankody(Memorial Sloan Kettering Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment